U.S. Markets closed

  • S&P 500

    3,426.92
    -56.89 (-1.63%)
     

  • Dow 30

    28,195.42
    -410.89 (-1.44%)
     

  • Nasdaq

    11,478.88
    -192.67 (-1.65%)
     

  • Russell 2000

    1,613.63
    -20.18 (-1.24%)
     

  • Crude Oil

    40.77
    -0.06 (-0.15%)
     

  • Gold

    1,906.70
    -5.00 (-0.26%)
     

  • Silver

    24.50
    -0.19 (-0.78%)
     

  • EUR/USD

    1.1776
    +0.0048 (+0.4122%)
     

  • 10-Yr Bond

    0.7610
    +0.0170 (+2.28%)
     

  • Vix

    29.18
    +1.77 (+6.46%)
     

  • GBP/USD

    1.2948
    +0.0039 (+0.3056%)
     

  • USD/JPY

    105.4500
    +0.0560 (+0.0531%)
     

  • BTC-USD

    11,736.17
    +679.17 (+6.14%)
     

  • CMC Crypto 200

    239.16
    +5.49 (+2.35%)
     

  • FTSE 100

    5,884.65
    -34.93 (-0.59%)
     

  • Nikkei 225

    23,671.13
    +260.50 (+1.11%)
     

Earnings Outlook for Volt Information Sciences

Benzinga Insights
·1 min read

On Thursday, September 10, Volt Information Sciences (AMEX: VOLT) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Earnings and Revenue

Analysts are predicting Volt Information Sciences will report a loss of $0.21 per share on revenue of $184.50 million. In the same quarter last year, Volt Information Sciences posted a loss of $0.21 per share on sales of $233.18 million. The analyst consensus estimate would represent no change in the company's earnings on a year over year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Quarter

Q2 2020

Q1 2020

Q4 2020

Q3 2019

EPS Estimate

-0.41

-0.26

-0.03

-0.20

EPS Actual

-0.23

-0.45

0.04

-0.21

Revenue Estimate

209.50 M

219.25 M

259.00 M

241.50 M

Revenue Actual

207.28 M

217.77 M

258.41 M

233.18 M

Stock Performance

Over the last 52-week period, shares are down 63.46%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.

View more earnings on VOLT

Don't be surprised to see the stock move on comments made during its conference call. Volt Information Sciences is scheduled to hold the call at 17:00:00 ET and can be accessed here: http://public.viavid.com/player/index.php?id=141418

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Latest Stories

  • 10 countries where you can retire on just $100,000

    Get the most from your retirement savings in these affordable places outside the U.S.

  • Dow Jones Futures Rise On Stimulus Deal Progress After Stock Market Rally Sell-Off; Apple Forges New Buy Point

    Futures rise on stimulus deal hopes after stocks sold off on stimulus deal pessimism. Yep. Also, Apple has a new buy point, but with flaws. Several other giants are forging handles.

  • The Bottom Is in for These 3 Stocks? Analysts Say ‘Buy’

    Markets thrive on risk, but risk is hard to talk about. It’s easy to fall back on cliches – buy low and sell high, or the bulls and bears make money while the pigs get slaughtered – but those cliches have drifted into common parlance for a reason. They have a grain of truth.Buying low and selling high has always been known as the way to make a profit, from the earliest days of human barter. And whether the market is moving up or down, whether investors follow a bullish or a bearish strategy, it’s possible to turn that profit.So, let’s talk about buying low. While the overall market has recovered nicely from the pandemic swoon of mid-winter, many stocks are still struggling with a depressed share value. Some of them are fundamentally sound – and Wall Street’s analysts have taking note.Using TipRanks database, we pinpointed three such stocks. Each is down at least 60% so far this year, but each also has a Strong Buy consensus rating and at least 40% upside potential for the coming months.Diamondback Energy (FANG)First up is Diamondback Energy, a Texas oil company that has been part of the Permian Basin boom which put Texas once again at the forefront of the North American oil industry. Diamondback is a smaller player in its industry and its operations are entirely within the Permian, where it is producing some 170,000 barrels of oil daily. While this number is up 40,000 barrels from the springtime, Diamondback has been hit hard by low oil prices in recent months and the stock is down 68% year-to-date.The low prices on the open oil market have impacted Diamondback’s bottom line, and earnings have been falling steadily from their $1.93 per share peak in 4Q19. The 1Q20 EPS was $1.45, while Q2 earnings came in at just 15 cents. The company is set to release third quarter figures on November 3, and the outlook calls for 37 cents – an improvement, but still down. However, it’s important to note here that Diamondback has beaten the earnings forecasts in the last three quarters.On a more positive note, company management points out that despite recent low earnings, FANG was able to end Q3 without touching its revolving credit facility – and that the company has over $2 billion in liquid assets available. Combined with rising production, this gives the company a solid footing.JPMorgan analyst Arun Jayaram, looking at the Texas oil sector and Diamondback’s place in it, sees the company as well-positioned to survive in a low-price environment. “We have consistently viewed FANG as one of the top-tier operators in the industry, and given the recent weakness in oil prices, the mgmt. team has made the prudent decision to sharply reduce activity levels. Given a focus on continuous cost reduction, we believe the company has the inventory depth and balance sheet strength to be a relative outperformer through the downturn,” Jayaram wrote.Jayaram rates FANG shares an Overweight (i.e. Buy), and his $48 price target suggests a 68% upside potential by next year. (To watch Jayaram’s track record, click here)Overall, the Strong Buy consensus rating on FANG is based on 11 recent Buys against a single Hold. The stock is selling for $28.58 per share, and its $52.10 average price target is even more bullish than Jayaram’s, implying an upside of 82%. (See FANG stock analysis on TipRanks)ChampionX Corporation (CHX)Next up is ChampionX, an oilfield technology company acquired its current name this past summer, through the merger of Apergy Corporation and ChampionX Holdings. The combined company kept Apergy’s trading history, and took on the new ticker, CHX. This is a midstream company with operations in the drilling, production, pipeline, and water technology segments of the oil industry. It’s a diversified portfolio of operations that gives ChampionX plenty of room to maneuver in a bearish oil market.ChampionX may need all of that maneuvering room, as the shares are down 76% this year. As with Diamondback, the chief culprit is low oil prices cutting into profit margins. Even though, as a midstream and service company, ChampionX does not directly pull the oil out of the ground and sell it, its operations are tied to the end users’ purchase price. In 2Q20, EPS turned sharply negative with a 43-cent per share net loss. This comes even as revenues rose in Q2, to $298 million.Scotiabank analyst Vaibhav Vaishnav sees CHX in a good place after improving its positioning as a services company.“With the merger with Ecolab’s Upstream business, CHX is now among the top two players in the production chemicals business. This business is relatively very stable as it focuses on production rather than drilling and completions activity. Essentially, daily U.S. or international oil production is the primary driver," Vaishnav opined. To this end, Vaishnav rates CHX an Outperform (i.e. Buy) rating. He gives the stock a $12 price target, indicating confidence in 48% upside growth for the coming year. (To watch Vaishnav’s track record, click here)Overall, CHX has 6 Buys and 1 Hold supporting its Strong Buy consensus rating. With a bullish average price target of $14.09, Wall Street’s analysts see a 73% upside potential from the current share price of $8.11. (See CHX stock analysis on TipRanks)Gol Linhas (GOL)From the oil industry, we move to the airline industry. It should come as no surprise that an airline, even a budget carrier, would face serious difficulties in the current environment of social distancing, trade and travel restrictions and disruptions, and economic shutdowns. Gol Linhas is Brazil’s premier low-cost air carrier, and the country’s third-largest airline. The difficulties facing the airline industry are apparent in GOL’s 62% share price decline since the start of the year.The hit Gol Linhas has taken is clear from the revenues and earnings. At the top line, the 17% sequential revenue drop in Q1 deepened to 88% in Q2, when the company brought in just $357 million. Quarterly revenues for GOL were above $3.8 billion before the corona crisis.The drop in revenue brought a serious loss in earnings. The company typically sees a drop off from Q4 to Q1 in earnings, and this year was no exception. The bright spot was, Q1 beat the forecast and beat the year-ago number. Q2, however, was disastrous, with an 81-cent EPS net loss. While not as deep as the $1.10 expected, it was a serious hit for the company. The outlook for Q3 is no better, at minus 80 cents.The long-term, however, looks better for this budget carrier. Deutsche Bank analyst Michael Linenberg sees GOL with several paths forward – although he believes that real returns will not come in until after 2021. "As we believe 2020 and 2021 will not be representative of GOL’s normal earnings potential, we are basing our 12-month PT on our 2022 forecast as GOL and the global airline industry begin to recover from the effects of COVID-19," the 5-star analyst noted.In line with this long-term optimism, Linenberg sets a $10 price target, implying an upside of 40% over the next 12 months. Accordingly, he rates the stock a Buy. (To watch Linenberg’s track record, click here)Wall Street agrees with Linenberg on the long-term potential here, and GOL’s Strong Buy consensus rating is based on a unanimous 5 Buys. (See GOL stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • ‘We bet on the wrong horse’: I co-signed my nephew’s $55K student loan: He has no degree and no job. What should we do?

    My wife and I co-signed her nephew’s student loans so he could attend a small private college. You loaned money to your nephew by co-signing his loan with the expectation that he would finish college, get a job and repay it. In other words, you co-signed the loan so your nephew would make the investment in his own future.

  • Is Boeing Stock A Buy Right Now As 737 Max Nears Return?

    Is Boeing stock a good buy now as coronavirus ravages aviation? Look at the aerospace giant's fundamentals and stock chart.

  • AT&T stock heads for lowest close since March

    Apple Inc.'s iPhone 12 launch hasn't driven much momentum for AT&T Inc. shares, which are on track for their lowest close in almost seven months.

  • Many stock investors are too young to remember Black Monday in October 1987 — why that’s a problem

    At some point over the next century, the stock market will lose more than 20% of its value in a single day. Maybe this doesn’t seem like useful advice, but the fact is that you’re kidding yourself if you think market crashes of such magnitude won’t happen again. This sobering thought coincides with the 33rd anniversary of the 1987 U.S. stock market crash.

  • Stock Market Today With Jim Cramer: Buy Boeing

    Jim Cramer discusses the latest stock market news including the return of the Boeing 737, Abbott and the deal between ConocoPhillips and Concho.

  • Intel Nearing Deal To Sell Memory-Chip Unit To SK Hynix: Report

    Chipmaker Intel is nearing a deal to sell its memory-chip business to South Korea's SK Hynix for about $10 billion, the Wall Street Journal reported Monday. Intel stock rose on the news.

  • Liz Weston: Playing the market is a bad idea, especially now

    The current day trading boom will end as these frenzies always do: in tears. While we wait for the inevitable crash, let’s review not only why day traders are doomed but also why most people shouldn’t trade, or even invest in, individual stocks. Day trading basically means rapidly buying and selling investments, hoping to profit from small price fluctuations.

  • Value stocks ‘worst for 100 years’

    If you have any old-fashioned “value” or “equity income” funds in your 401(k), IRA or other retirement accounts, right about now you may be asking yourself, or your financial adviser, some very awkward questions. Strategists divided the stock market cleanly into “value” and “growth” halves. Morningstar (MORN) the fund-research company, says the average U.S. large company “value” mutual fund has lost 8% so far this year, even including reinvested dividends.

  • What Just Happened to NIO Stock — and What Investors Should Do About It

    Stock in the Chinese electric-vehicle maker was on fire last week, leaving some on Wall Street wondering what happened and investors wondering what comes next.

  • When retirement arrives sooner than expected: What to do, what to know

    Although Americans typically assume they will retire when they want, and on their own terms, many are in for a surprise

  • Tesla Analyst Raises Price Target To $500 Ahead Of Q3 Print

    With Tesla Inc (NASDAQ: TSLA) scheduled to report third-quarter results Wednesday, an analyst at Wedbush is optimistic that the electric vehicle giant will outperform expectations.The Tesla Analyst: Daniel Ives maintained a Neutral rating on Tesla shares and increased the price target from $475 to $500.The Tesla Thesis: The focus is likely to be on Tesla's level of third-quarter profitability and the unit growth trajectory into the fourth quarter, Ives said in a Monday note. The company is poised to report a bottom-line beat, helped by manufacturing efficiency and shining Giga3 success in China, the analyst said.Full-year deliveries are on track to hit the company's guidance of 500,000, as Tesla navigated the unprecedented COVID-19 backdrop, he said. "We believe with a strong 4Q that Tesla will be on a pace to hit the 500k threshold as pent up China demand and pockets of strength within Europe remains the linchpin to the demand resurgence that Musk & Co. have seen over the past few quarters," Ives said. Related Link: What To Expect When Tesla's Q3 Report Drops Next Week View more earnings on TSLAWith China expected to account for over 40% of Tesla's global sales potentially by early 2022, Tesla's profitability profile will improve, as Model 3s sold in China have higher margins, the analyst said.Along with more leverage on the horizon out of Giga 3, more price cuts both in the U.S. and China could stimulate demand further, he said. "Steady profitability after years of red ink has been the 'hearts and lungs' to the bull thesis on the Street and a key ingredient in the stock's performance this year." The overall EV market is still in the early days of playing out globally, according to Wedbush.Tesla is in a formidable position to maintain its leadership position despite competitors coming from every angle globally, Ives said. TSLA Price Action: Tesla shares were down 0.49% at $437.53 at last check Monday. Related Link: Tesla Analyst Sees Disconnect Between Share Price, EV Company's Fundamentals Photo courtesy of Tesla. Latest Ratings for TSLA DateFirmActionFromTo Oct 2020WedbushMaintainsNeutral Oct 2020Morgan StanleyMaintainsEqual-Weight Oct 2020Goldman SachsMaintainsNeutral View More Analyst Ratings for TSLA View the Latest Analyst Ratings See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Tesla Battery Supplier LG Chem Preannounces 159% Profit Growth * Tesla Analyst Sees Disconnect Between Share Price, EV Company's Fundamentals(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • IBM revenue edges past estimates on cloud strength

    The results come just weeks after Big Blue surprised investors with its announcement of splitting itself into two public companies, placing big bets on cloud computing to drive its future growth. "We continue to see a very strong pattern in acceleration of our clients' digital transformation ... We are seeing that play out in our Red Hat business," Chief Financial Officer James Kavanaugh told Reuters. IBM's total revenue fell 2.6% to $17.56 billion in the reported quarter, but was slightly above analysts' estimates of $17.54 billion, according to IBES data from Refinitiv.

  • Wall Street Is Preparing for a Biden Victory, Higher Taxes and All

    While the wealthy and corporations might have to reach deeper into their pockets to pay Uncle Sam, tax-exempt municipal bonds could emerge as a big winner.

  • Biden’s Clean Grid Would Choke Gas, Even Without Fracking Ban

    (Bloomberg) -- During a town hall meeting Thursday, Democratic presidential nominee Joe Biden again assured shale producers that he wouldn’t ban fracking if elected. Then, in virtually the same breath, he touted his $2 trillion clean-energy plan, which aims to edge natural gas out of the power mix within 15 years.The former vice president’s efforts to walk a tightrope on gas reflect the fossil fuel’s precarious place in the economy. For now, it’s an essential part of American life. Biden has been careful not to make an enemy of the industry, especially in the key battleground state of Pennsylvania, home to the largest U.S. shale-gas field. His policies may even, in the short-term, support the gas market.But in the long run, the fuel may prove economically and environmentally untenable within the power sector, a key market for producers. Biden’s climate plan would only accelerate that outcome, with massive investments in wind, solar and battery storage giving those energy sources a leg up. And his goal of a carbon-neutral grid would severely curb, if not destroy, gas’s share of the pie in favor of cheaper, cleaner renewables.“Decarbonization isn’t a debate -- it’s a fossil-fuel death sentence,” said Kevin Book, managing director of ClearView Energy Partners. “It means a resource is going off the grid. That is the inevitable implication.”Gas, like coal a decade ago, is facing economic headwinds. While it’s still the nation’s dominant fuel source, it’s less competitive against renewables than it used to be. Solar and wind are now cheaper than gas-fired power in two-thirds of the world, according to a BloombergNEF report. In the U.S., solar and wind are already less expensive than even the most efficient type of new gas-fired turbine, Lazard Ltd. said Monday.The right combination of federal policies could easily push gas out of the power mix by 2035 or earlier.“This transition is going to happen more quickly than people thought, just as the coal transition has happened faster than people thought it would,” said John Coequyt, the climate policy director at the Sierra Club.To be sure, gas may reap some benefits from a Biden presidency in the near-term. Though his proposal to limit drilling on federal lands could trim production, tighter supplies could lift prices, potentially making gas exports more profitable. Similarly, a thaw in U.S.-China relations could give exporters greater access to a major world market.But higher prices would have the opposite effect in the power sector, where cost is key. Gas-fired electricity generation is already expected to fall 5.7% this winter compared to last year simply because gas prices are higher this season, according to Energy Information Administration projections. And that’s despite forecasts for a colder winter, which would increase electricity demand.The economics put gas in a roughly similar position as coal in the years before President Barack Obama took office.In coal’s case, Obama hastened its decline by imposing new environmental regulations that made coal plants more costly to operate – notably the 2012 Mercury and Air Toxics Standards that limited toxic emissions from plants, and the 2015 Clean Power Plan that curbed carbon emissions.A Biden administration could take a similar tack, imposing new -- and more stringent -- limits on greenhouse gas emissions from power plants. He could also reinstate and possibly strengthen Obama-era rules curbing methane leaks from gas infrastructure, which were repealed by President Donald Trump. Both have the potential to drive up the cost of gas-fired electricity, without banning the fuel.Most analysts agree that Biden wouldn’t explicitly go after the gas industry in the same way that Obama attacked the coal sector. Instead, Biden’s clean-energy policies would make it harder for gas to compete with wind, solar and other renewables.“You might be able to adopt policies that at least give them a theoretical chance to survive, even if they’re going to make it much harder for them to survive,” said David Spence, a professor at the University of Texas School of Law.For now, there isn’t much pressure to close the gas plants already in service. “Existing gas plants will have a role to play for a while,” said Mark Dyson, a principal at the Rocky Mountain Institute. “They’re keeping the lights on while we build as much wind and solar as we can.”And Biden’s proposal leaves the door open for utilities to continue using gas plants that are fitted with carbon-capture systems that trap emissions, said Jonathan Elkind, senior research scholar at Columbia University’s Center on Global Energy Policy.In Thursday’s town hall, Biden stressed the importance of embracing “new technologies,” including carbon capture, as a way to achieve a carbon-free electricity sector while still using some natural gas.Still, utilities might not want to make that kind of investment when the price of renewables continues to fall.“A lot of the path to net-zero by 2035 for power will come from energy efficiency gains, a lot from renewables, and that will squeeze out fossil fuels eventually,” said Katie Bays, an analyst with Sandhill Strategy in Washington.Already, local jurisdictions are moving away from gas in pursuit of their own climate goals. Cities across California have moved to ban natural gas use in homes, while New York blocked a proposed $1 billion pipeline that Governor Andrew Cuomo. Opposition by environmental groups even drove Dominion Energy Inc. to cancel a major pipeline project before selling most of its gas operations in July.Utilities are also preparing for a gas-less future. Besides building renewables, power giants NextEra Energy Inc. and Entergy Corp. are among companies investing in gas turbines that can transition to running on 100% renewable hydrogen.Still, many doubt whether it’s even possible to achieve a carbon-free power grid in 15 years, which is a more ambitious goal than California and New York have set for themselves. Transforming the electric grid would be both costly and complicated and analysts caution against taking the plan too literally.To pay for it, Biden has proposed an increase in the corporate income tax rate to 28% from 21% as well as using stimulus money. But that would require congressional approval, a tall order if Republicans retain control of the Senate.Nevertheless, the push for decarbonization reflected in the Biden plan presents a real, long-term threat to natural gas as a source of electricity.“There would be a huge downside risk for gas demand,” said Carlos Torres Diaz, head of gas and power market research at Rystad Energy AS, in Oslo. “Even if we don’t get to zero.”(Adds Lazard analysis in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • IBM stock slips after another revenue decline, no outlook

    International Business Machines Corp. revenue continued to decline in the third quarter, according to a Monday report, and shares sank in after-hours trading following the earnings report.

  • Stock market news live updates: Wall Street slumps on fading pre-election stimulus hopes, Dow has worst day in nearly a month

    A selloff Monday accelerated as investors continued to weigh fading prospects of a near-term stimulus package, and eyed still-rising coronavirus cases in the U.S.

  • These 3 Penny Stocks Have Massive Upside Potential, Says Cowen

    It’s a mixed bag when it comes to opinions on penny stocks. These tickers trading for less than $5 per share divide Wall Street like no other; market watchers either love them or hate them.It’s easy to understand the appeal. First and foremost, you get more bang for your buck. On top of this, with shares changing hands for bargain prices, even what seems like miniscule share price appreciation can translate to monstruous percentage gains. For some, however, the risk poses too great a threat to ignore. When you look under the hood of these low-priced names, you might find very real problems like poor fundamentals or looming headwinds.So, how are investors supposed to spot the penny stocks poised to go from rags to riches? By turning to the pros.With this in mind, we wanted to take a closer look at three penny stocks getting love from the pros, namely the analysts at investment firm Cowen. According to the firm, all three could soar in the year ahead. Using TipRanks’ database, we learned why Cowen analysts are pounding the table despite the risk involved.Neos Therapeutics (NEOS)Developing and commercializing innovative products, Neos Therapeutics wants to make a significant difference in the lives of patients with Attention Deficit Hyperactivity Disorder (ADHD) and other central nervous system (CNS) conditions. Although this name has struggled in the past, Cowen thinks that at $0.47 apiece, now is the time to snap up shares.Writing for the firm, analyst Ken Cacciatore acknowledges the momentum that was being driven by Adzenys XR-ODT, the company’s amphetamine-based treatment for ADHD, and Cotempla, its methylphenidate-based CNS stimulant also designed for ADHD, has slowed due to the pandemic. However, based on recent prescription trends, the analyst is seeing “signs of recovery ahead of the back to school (via video/classroom) acceleration in Q4.”Expounding on this, Cacciatore stated, “We continue to believe that management is taking the rights steps with the strategic improvements which seem to be benefiting from the more targeted prescriber base focus and more rapid adoption of the newco-pay assistance/fulfillment program (Rx Connect), to improve the profitability per prescription. And given what appears to be its early success of Rx Connect alongside spending reduction plan and salesforce restructuring we believe Neos could reach profitability by early 2022.”As the net revenue per pack for Adzenys and Cotempla grew 6% year-over-year to reach $128, Cacciatore argues the company’s efforts are paying off. “Again, we believe these data points appear to reflect the improved commercial approach, and the effectiveness of the company's Neos Rx Connect pharmacy program which simplifies the previously more complex prescription fulfillment and co-pay assistance,” he commented.By enabling this access with Rx Connect, physicians can write prescriptions for Cotempla and Adzenys without worrying about patient call-backs. According to management, 30% of prescriptions are currently fulfilled through this program, and after multiple large regional pharmacy chains were added, the total number of partnered pharmacies was almost 900 in June, compared to 800 at the end of Q1.What’s more, the fact that NEOS is the only company to have both a methylphenidate and amphetamine alternate dose formulation product for the treatment of ADHD is enough to make it a stand-out, in Cacciatore’s opinion. Calling Cotempla the “perfect complement to Adzenys,” he notes that each asset covers one half of the large stimulant market.The analyst added, “Adzenys XR-ODT has experienced impressive prescription growth over the course of the past year, and is now the preferred ADHD alternative dosage form taking over from Pfizer's market-leading Quillivant XR as its new-to-brand market share reached the number 1 position.”Also promising, NEOS offers Adzenys ER, which is an extended-release liquid suspension stimulant product for ADHD. The product is amphetamine-based like Adzenys XR-ODT, but is an alternative dosage form for patients who don’t prefer tablets or capsules. Cacciatore points out that success with the liquid alternative dosage form has already been demonstrated as Pfizer’s Quillivant XR generated over $100 million in annual sales in 2017.To this end, Cacciatore rates NEOS an Outperform (i.e. Buy) along with an $8 price target. Should the target be met, a twelve-month gain in the shape of a whopping 1,604% could be in store. (To watch Cacciatore’s track record, click here)Turning now to the rest of the Street, 3 Buys and no Holds or Sells have been published in the last three months. Therefore, NEOS has a Strong Buy consensus rating. At $8.33, the average price target is even more aggressive than Cacciatore’s and implies 1674% upside potential. (See NEOS stock analysis on TipRanks)Dynavax Technologies (DVAX)Bringing extensive expertise in Toll-like Receptor (TLR) biology and cutting-edge adjuvant technology to the table, Dynavax develops vaccines to protect the population. Thanks to its promising pipeline and $4.30 share price, Cowen believes investors should get in on the action.Representing the firm, 5-star analyst Phil Nadeau cites Heplisav as a key component of his bullish thesis. The product is an HBV vaccine that has been shown to be more effective than the other currently marketed HBV vaccines in a number of Phase 3 trials. Based on commentary from the firm’s consultants, he argues the asset could capture a significant portion of the $500 million-plus worldwide market for adult HBV vaccines.Also contributing to Nadeau’s optimistic stance, DVAX has agreed to several partnerships to further explore if CpG 1018, the adjuvant in Heplisav, can improve the efficacy of other vaccines.In September, DVAX announced its supply agreement with Valneva to produce up to 190 million doses over five years of Valneva's COVID-19 vaccine candidate, VLA2001. This vaccine is an inactivated whole virus vaccine against the SARS-CoV-2 virus, and will incorporate DVAX's CpG 1018 adjuvant. Clinical trials are expected to kick off by YE, with approval potentially coming in 2H21. In addition, the UK government has secured a supply of 60 million doses for €470 million, and there is an option for another 130 million doses for approximately €900 million.DVAX has already conveyed that it wants to make CpG 1018 a broadly used adjuvant, and has been making “rapid progress in implementing it,” says Nadeau. He notes that this deal is consistent with this strategy, and “in some ways represents a next step.” He added, “The supply agreement is notable as it helps demonstrate the economics that successful development of partnered vaccines could bring.”According to the company’s guidance, CpG 1018 could capture 15-30% of the economics when used in partnered vaccines. “Though management has not disclosed the exact economics in the Valneva collaboration, we believe they are consistent with DVAX's guidance and suspect they are toward the middle of the range,” Nadeau commented.“In our opinion DVAX is significantly undervalued for the potential of Heplisav and the CpG 1018 adjuvant,” Nadeau concluded.It should come as no surprise, then, that Nadeau sides with the bulls. Along with an Outperform (i.e. Buy) rating, he puts a $20 price target on the stock, indicating 370% upside potential. (To watch Nadeau’s track record, click here)Other analysts echo Nadeau’s sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $16, the upside potential comes in at 276%. (See DVAX stock analysis on TipRanks)La Jolla Pharmaceutical (LJPC)Last but not least we have La Jolla Pharmaceutical, which develops innovative therapies for life-threatening diseases with significant unmet need. Given its impressive technology, Cowen sees its $4 share price as presenting an attractive entry point.Analyst Phil Nadeau, who also covers DVAX for the firm, highlights LJPC’s first commercial product, Giapreza, a patented formulation of the naturally occurring hormone peptide, angiotensin II, as a point of strength. Angiotensin II is a potent vasoconstrictor and a key regulator of blood pressure.The launch has been rocky, with the pandemic hitting the acute care in-hospital segment hard. That said, Nadeau remains optimistic. “...our consultants think there is a need for new vasopressors in CRH, and therefore we remain hopeful that Giapreza can ramp to become a meaningful product over time,” he explained.On top of this, in July, LJPC acquired Tetraphase, giving it the rights to Xerava, a novel fluorocycline antibacterial designed for the treatment of complicated intra-abdominal infections. Even though the therapy’s utilization was most likely impacted by COVID-19, Nadeau has high hopes for the product.Nadeau argues LJPC will be able to leverage its existing infrastructure to market and promote Xerava, with only minimal additional spend expected.“Though Xerava has many competitors, the market for antibiotics used to treat intra-abdominal infections is large -- patients with appendicitis alone contribute to over 1 million hospital days each year in the U.S. Thus, with promotion, Xerava should continue to grow,” the analyst said. To this end, Nadeau projects $15 million in Xerava revenue in 2021, with this figure ramping to $60 million in 2024.Summing it all up, Nadeau stated, “Trading with a modest enterprise value, La Jolla is undervalued should Giapreza and Xerava be successfully commercialized.”Taking the above into consideration, Nadeau rates LJPC an Outperform (i.e. Buy) rating along with a $20 price target. This target conveys his confidence in LJPC’s ability to climb 402% higher in the next year.What does the rest of the Street have to say? When it comes to other analyst activity, it has been relatively quiet. 2 Buys and no Holds or Sells have been issued in the last three months. Therefore, LJPC gets a Moderate Buy consensus rating. Based on the $14 average price target, shares could skyrocket 251% in the next year. (See LJPC stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.